Movement Alert｜WUXI APPTEC Rises 3.12% in Regular Trading, CXO Sector Rallies on Sustained Recovery Momentum

Market Focus09-14 10:28

On September 14, WUXI APPTEC rose 3.12% in regular trading, trading at 194.9 HKD/share, with turnover of 151 million HKD. The gain came amid a broad rally across the Life Sciences Tools & Services sector, with peers PHARMARON up 5.88%, GENSCRIPT BIO up 3.34%, and WUXI BIO up 3.06%.

The sector-wide strength follows a wave of bullish institutional coverage on the CRO/CDMO industry. Goldman Sachs recently highlighted that the sector's recovery is broadening, with WUXI APPTEC's backlog reaching RMB 66.43 billion, up 25.2% year-over-year, and full-year revenue growth guidance raised to 35%-39%. Morgan Stanley maintained an Overweight rating and lifted the target price to 220 HKD, citing improved earnings visibility. Meanwhile, the company announced early redemption of its outstanding RMB 4.973 billion zero-coupon convertible bonds due 2027, signaling management confidence in its cash position and operational outlook.

Additionally, the company raised its mid-term dividend to RMB 1.51 billion and increased adjusted free cash flow guidance to RMB 13.5-14.5 billion, underscoring robust cash generation quality.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129986724?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129986724","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI APPTEC Rises 3.12% in Regular Trading, CXO Sector Rallies on Sustained Recovery Momentum","media":"Market Focus","content":"<p><p>On September 14, WUXI APPTEC rose 3.12% in regular trading, trading at 194.9 HKD/share, with turnover of 151 million HKD. The gain came amid a broad rally across the Life Sciences Tools & Services sector, with peers PHARMARON up 5.88%, GENSCRIPT BIO up 3.34%, and WUXI BIO up 3.06%.</p><p>The sector-wide strength follows a wave of bullish institutional coverage on the CRO/CDMO industry. Goldman Sachs recently highlighted that the sector's recovery is broadening, with WUXI APPTEC's backlog reaching RMB 66.43 billion, up 25.2% year-over-year, and full-year revenue growth guidance raised to 35%-39%. Morgan Stanley maintained an Overweight rating and lifted the target price to 220 HKD, citing improved earnings visibility. Meanwhile, the company announced early redemption of its outstanding RMB 4.973 billion zero-coupon convertible bonds due 2027, signaling management confidence in its cash position and operational outlook.</p><p>Additionally, the company raised its mid-term dividend to RMB 1.51 billion and increased adjusted free cash flow guidance to RMB 13.5-14.5 billion, underscoring robust cash generation quality.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI APPTEC Rises 3.12% in Regular Trading, CXO Sector Rallies on Sustained Recovery Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI APPTEC Rises 3.12% in Regular Trading, CXO Sector Rallies on Sustained Recovery Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, WUXI APPTEC rose 3.12% in regular trading, trading at 194.9 HKD/share, with turnover of 151 million HKD. The gain came amid a broad rally across the Life Sciences Tools & Services sector, with peers PHARMARON up 5.88%, GENSCRIPT BIO up 3.34%, and WUXI BIO up 3.06%.</p><p>The sector-wide strength follows a wave of bullish institutional coverage on the CRO/CDMO industry. Goldman Sachs recently highlighted that the sector's recovery is broadening, with WUXI APPTEC's backlog reaching RMB 66.43 billion, up 25.2% year-over-year, and full-year revenue growth guidance raised to 35%-39%. Morgan Stanley maintained an Overweight rating and lifted the target price to 220 HKD, citing improved earnings visibility. Meanwhile, the company announced early redemption of its outstanding RMB 4.973 billion zero-coupon convertible bonds due 2027, signaling management confidence in its cash position and operational outlook.</p><p>Additionally, the company raised its mid-term dividend to RMB 1.51 billion and increased adjusted free cash flow guidance to RMB 13.5-14.5 billion, underscoring robust cash generation quality.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"","article_id":"1129986724","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129986724","pubTimestamp":1789352886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, WUXI APPTEC rose 3.12% in regular trading, trading at 194.9 HKD/share, with turnover of 151 million HKD. The gain came amid a broad rally across the Life Sciences Tools & Services...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02359":"药明康德"},"translate_title":"走势提醒|药明康德常规交易上涨3.12%，CXO板块持续复苏势头反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"On September 14, WUXI APPTEC rose 3.12% in regular trading, trading at 194.9 HKD/share, with turnover of 151 million HKD. The gain came amid a broad rally across the Life Sciences Tools & Services sector, with peers PHARMARON up 5.88%, GENSCRIPT BIO up 3.34%, and WUXI BIO up 3.06%.The sector-wide strength follows a wave of bullish institutional coverage on the CRO/CDMO industry. Goldman Sachs recently highlighted that the sector's recovery is broadening, with WUXI APPTEC's backlog reaching RMB 66.43 billion, up 25.2% year-over-year, and full-year revenue growth guidance raised to 35%-39%. Morgan Stanley maintained an Overweight rating and lifted the target price to 220 HKD, citing improved earnings visibility. Meanwhile, the company announced early redemption of its outstanding RMB 4.973 billion zero-coupon convertible bonds due 2027, signaling management confidence in its cash position and operational outlook.Additionally, the company raised its mid-term dividend to RMB 1.51 billion and increased adjusted free cash flow guidance to RMB 13.5-14.5 billion, underscoring robust cash generation quality.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129986724","isCrawlerRequest":true}